



Neurology[®]

April 05, 2016; 86 (16 Supplement) APRIL 18, 2016

Efficacy of Cladribine Tablets as Add-On to IFN-beta Therapy in Patients with Active Relapsing MS: Final Results from the Phase II ONWARD Study (P3.029)

Xavier Montalban, Bruce Cohen, Thomas Leist, Harold Moses, Christine Hicking, Fernando Dangond


First published April 4, 2016,

“ CITATION	🔒 PERMISSIONS
✎ MAKE COMMENT	💬 SEE COMMENTS



Downloads { 0

SHARE



Article Information

vol. 86 no. 16 Supplement P3.029

Published By: Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology

Print ISSN: 0028-3878

Online ISSN: 1526-632X

History:

- First Published April 4, 2016.

Copyright & Usage: Copyright © 2016 by AAN Enterprises, Inc.

Author Disclosures

Xavier Montalban₃, Bruce Cohen₄, Thomas Leist₅, Harold Moses₆, Christine Hicking₂ and Fernando Dangond₁

1. ☐ Xavier Montalban₃,
2. ☐ Bruce Cohen₄,
3. ☐ Thomas Leist₅,
4. ☐ Harold Moses₆,
5. ☐ Christine Hicking₂ and
6. ☐ Fernando Dangond₁

1. ¹EMD Serono, Inc. Billerica MA United States

2. ²Merck KGaA Darmstadt Germany

3. ³*Multiple Sclerosis Center of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron Barcelona Spain*
4. ⁴*Northwestern University, Feinberg School of Medicine Chicago IL United States*
5. ⁵*Thomas Jefferson University Philadelphia PA United States*
6. ⁶*Vanderbilt University Medical Center Nashville TN United States*

Article usage

ARTICLE LIFETIME	LAST 6 MONTHS	THIS MONTH
------------------	---------------	------------

Article usage: April 2016 to December 2022

	Abstract	Full	Pdf	Source
Apr 2016	38	0	0	Highwire
May 2016	7	0	0	Highwire
Jun 2016	11	0	0	Highwire
Jul 2016	16	0	0	Highwire
Aug 2016	15	0	0	Highwire
Sep 2016	36	0	0	Highwire
Oct 2016	48	0	0	Highwire
Nov 2016	52	0	0	Highwire
Dec 2016	12	0	0	Highwire
Jan 2017	42	0	0	Highwire
Feb 2017	87	0	0	Highwire
Mar 2017	84	0	0	Highwire
Apr 2017	136	0	0	Highwire

	Abstract	Full	Pdf	Source
May 2017	80	0	0	Highwire
Jun 2017	76	0	0	Highwire
Jul 2017	97	0	0	Highwire
Aug 2017	98	0	0	Highwire
Sep 2017	98	0	0	Highwire
Oct 2017	95	0	0	Highwire
Nov 2017	140	0	0	Highwire
Dec 2017	58	0	0	Highwire
Jan 2018	48	0	0	Highwire
Feb 2018	79	0	0	Highwire
Mar 2018	42	0	0	Highwire
Apr 2018	49	0	0	Highwire
May 2018	58	0	0	Highwire
Jun 2018	70	0	0	Highwire
Jul 2018	57	0	0	Highwire
Aug 2018	30	0	0	Highwire
Sep 2018	35	0	0	Highwire
Oct 2018	34	0	0	Highwire
Nov 2018	31	0	0	Highwire

	Abstract	Full	Pdf	Source
Dec 2018	21	0	0	Highwire
Jan 2019	20	0	0	Highwire
Feb 2019	32	0	0	Highwire
Mar 2019	19	0	0	Highwire
Apr 2019	49	0	0	Highwire
May 2019	20	0	0	Highwire
Jun 2019	17	0	0	Highwire
Jul 2019	13	0	0	Highwire
Aug 2019	4	0	0	Highwire
Sep 2019	13	0	0	Highwire
Oct 2019	12	0	0	Highwire
Nov 2019	17	0	0	Highwire
Dec 2019	1	0	0	Highwire
Jan 2020	11	0	0	Highwire
Feb 2020	2	0	0	Highwire
Mar 2020	3	0	0	Highwire
Apr 2020	7	0	0	Highwire
May 2020	4	0	0	Highwire
Jun 2020	5	0	0	Highwire

	Abstract	Full	Pdf	Source
Jul 2020	2	0	0	Highwire
Aug 2020	7	0	0	Highwire
Sep 2020	22	0	0	Highwire
Oct 2020	5	0	0	Highwire
Nov 2020	4	0	0	Highwire
Dec 2020	12	0	0	Highwire
Jan 2021	11	0	0	Highwire
Feb 2021	9	0	0	Highwire
Mar 2021	14	0	0	Highwire
Apr 2021	14	0	0	Highwire
May 2021	17	0	0	Highwire
Jun 2021	12	0	0	Highwire
Jul 2021	15	0	0	Highwire
Aug 2021	13	0	0	Highwire
Sep 2021	19	0	0	Highwire
Oct 2021	16	0	0	Highwire
Nov 2021	21	0	0	Highwire
Dec 2021	16	0	0	Highwire
Jan 2022	30	0	0	Highwire

	Abstract	Full	Pdf	Source
Feb 2022	35	0	0	Highwire
Mar 2022	25	0	0	Highwire
Apr 2022	27	0	0	Highwire
May 2022	21	0	0	Highwire
Jun 2022	27	0	0	Highwire
Jul 2022	28	0	0	Highwire
Aug 2022	28	0	0	Highwire
Sep 2022	26	0	0	Highwire
Oct 2022	36	0	0	Highwire
Nov 2022	40	0	0	Highwire
Dec 2022	54	0	0	Highwire

Letters: Rapid online correspondence

No comments have been published for this article.

 COMMENT

YOU MAY ALSO BE INTERESTED IN

MONDAY, APRIL 4

Comparative Effectiveness of Cladribine versus Fingolimod in the Treatment of Highly Active Relapsing Multiple Sclerosis: The MERLYN (MavEnclad Real worLd comparative efficacY non-iNterventional) Study (P7-4.005)

Wallace Brownlee, Aiden Haghikia, Brooke Hayward, et al.
May 03, 2022

SUNDAY, APRIL 24

Cladribine Tablets in Patients With Relapsing-Remitting Multiple Sclerosis or Active Secondary Progressive Multiple Sclerosis After Suboptimal Response to a Disease-Modifying Therapy (CLICK-MS and MASTER-2): Interim Baseline and Safety Review (P1-1.Virtual)

Augusto A. Miravalle, Joshua Katz, Derrick Robertson, et al.

May 03, 2022

RESEARCH ARTICLE

Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis

Izanne Roos, Charles Malpas, Emmanuelle Leray, et al.

August 17, 2022

SUNDAY, APRIL 24

A Cross-Sectional Survey Evaluating Cladribine Tablets Treatment Patterns Among Patients with Multiple Sclerosis Across the US Enrolled in the MS LifeLines Patient Support Program (P1-1.Virtual)

Jacqueline Nicholas, deMauri S. Mackie, Halley Costantino, et al.

May 03, 2022

TUESDAY, APRIL 5

Clinical Outcomes in Patients With COVID-19 During Two Phase IV Studies of Cladribine Tablets for Treatment of Multiple Sclerosis: An Update (P11-4.005)

Victoria Yavorskaya, Radmila Karan, Laszlo Borsi, et al.

May 03, 2022

[^ Back to top](#)

Advertisement



HEMIPLEGIC MIGRAINE ASSOCIATED WITH PRRT2 VARIATIONS A CLINICAL AND GENETIC STUDY

Dr. Robert Shapiro and Dr. Aynah Pradhan

► WATCH

RELATED ARTICLES

No related articles found.

ALERT ME

Alert me when eletters are published



Articles

Ahead of Print

Current Issue

Past Issues

Popular Articles

Translations

About

About the Journals

Ethics Policies

Editors & Editorial Board

Contact Us

Advertise

Submit

Author Center

Submit a Manuscript

Information for Reviewers

AAN Guidelines

Permissions

Subscribers

Subscribe

Activate a Subscription

Sign up for eAlerts

RSS Feed



Neurology

Neurology: Clinical Practice

Neurology: Education

Neurology: Genetics

Neurology: Neuroimmunology & Neuroinflammation

AAN.com

AANnews

Continuum

Brain & Life

Neurology Today



Wolters Kluwer

Neurology | Print ISSN:0028-3878

Online ISSN:1526-632X

© 2023 American Academy of Neurology

[Privacy Policy](#) [Feedback](#) [Advertise](#)